Neoadjuvant Pamiparib/Chemo Combo Leads to R0 Resections in Advanced Ovarian Cancer
Pamiparib with paclitaxel, carboplatin, and bevacizumab yields high complete cytoreduction rates, manageable safety in advanced ovarian cancer.
Related Articles
Five Under 5: Top Oncology Videos for the Week of 8/3
The top 5 OncLive videos of the week cover insights in renal cell carcinoma, glioma, multiple myeloma, and ovarian cancer.
FDA’s Published CRLs Deliver Insight Into the Drug Approval Process
Dive into each of the oncology-related CRLs that were recently released by the FDA, as well as relevant subsequent FDA decisions.
Classification Advances Guide Research and Precision Therapy in Non–Clear Cell RCC
Joseph Vento, MD, discusses how WHO updates and molecular profiling are shaping trial design and targeted treatment in non–clear cell RCC.
Nuanced Biomarker Tests and Immunotherapy Strategies May Usher ASCO 2025 Data Into the Clinic
Oncology experts share topline insights from 19 of the most exciting abstracts from the 2025 ASCO Annual Meeting.
Cilta-Cel Data Set a High Bar for Anito-Cel in Relapsed/Refractory Myeloma
Darren Pan, MD, discusses updates regarding cilta-cel and anito-cel for the treatment of patients with relapsed/refractory multiple myeloma.
Data for Elotuzumab Support Further Investigation in JAK Inhibitor–Based Combinations in Myelofibrosis
Safety and efficacy data for elotuzumab support its further investigation in the treatment of myelofibrosis.
Lutetium Lu 177 Vipivotide Tetraxetan Positioned for Earlier Use in mCRPC While Radium-223 Sequencing Requires Further Clarification
Qian (Janie) Qin, MD, discusses the current arsenal of radioligand therapies in metastatic castration-resistant prostate cancer.
KIM-1 Represents a Potential Biomarker for Outcomes and Response in RCC
KIM-1 levels have shown the ability to predict therapeutic benefit in patients with renal cell carcinoma.
FDA Issues CRL for Glofitamab Plus Chemo in R/R DLBCL
The FDA issued a CRL to the application for glofitamab plus chemotherapy in relapsed/refractory diffuse large B-cell lymphoma.
Luspatercept Plus Concomitant JAK Inhibitor Therapy Misses Primary End Point in Myelofibrosis-Associated Anemia
Luspatercept plus a concomitant JAK inhibitor didn’t meet the primary end point of 12-week RBC transfusion independence in myelofibrosis-associated anemia.